The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.
What Is The Estimated Growth In Market Size Of The G-CSF (Granulocyte Colony Stimulating Factors) Market During 2026–2030?
The market size for g-csf (granulocyte colony stimulating factors) has demonstrated consistent growth in recent years. It is anticipated to expand from $9.48 billion in 2025 to $9.94 billion in 2026, registering a compound annual growth rate (CAGR) of 4.8%. Historically, this growth has been influenced by factors such as the initial limited availability of g-csf therapies, the increasing prevalence of chemotherapy-induced neutropenia, a growing oncology patient population, regulatory approvals for first-generation g-csf products, and the widespread adoption of injectable formulations.
The market size for g-csf, or granulocyte colony stimulating factors, is anticipated to show significant expansion in the coming years. It is projected to reach $12.21 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 5.3%. This expected growth during the forecast period is attributed to several factors: the introduction of novel g-csf products, the expanding presence of biosimilars in emerging markets, a greater reliance on combination therapies, the increasing demand for pre-filled syringe formulations, and a rise in investment in supportive care and neutropenia management programs. Prominent trends for this period include a growing demand for g-csf biosimilars, wider adoption of pre-filled syringes and injectable formulations, an increase in combination therapies with other growth factors, the broader application of g-csf in oncology and blood disorder treatments, and increased awareness regarding neutropenia management and supportive care.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3466&type=smp
Which Strategic Drivers Are Supporting The G-CSF (Granulocyte Colony Stimulating Factors) Market Development?
The G-CSF (granulocyte colony stimulating factor) market is anticipated to expand due to the rising occurrence of cancer. Cancer is defined by the uncontrolled multiplication and dispersion of abnormal cells, leading to disruptions in normal bodily functions and potentially death. The growing incidence of cancer is driven by elements like aging demographics, evolving lifestyles, and environmental risk factors that increase susceptibility. The G-CSF market plays a crucial role in this context by supplying growth factors that encourage white blood cell generation, thereby mitigating the danger of infection and sepsis for cancer patients undergoing chemotherapy. For example, the National Health Service (NHS), a UK government health agency, reported 354,820 new cancer diagnoses in 2023, averaging 972 daily, which represented an increase of 8,605 from 2022, as noted in October 2025. Consequently, the expanding prevalence of cancer acts as a primary catalyst for the growth of the G-CSF (granulocyte colony stimulating factor) market.
Which Segment-Based Categories Are Covered In The G-CSF (Granulocyte Colony Stimulating Factors) Market?
The g-csf (granulocyte colony stimulating factors) market covered in this report is segmented –
1) By Type: Pegfilgrastim, Lenograstim, Filgrastim, Other Types
2) By Product Form: Tablet, Capsule, Other Product Forms
3) By Application: Oncological Diseases, Blood Disorders, Chronic And Autoimmune Disorders, Other Applications
Subsegments:
1) By Pegfilgrastim: Pre-filled Syringes, Vial Formulations, Biosimilars Of Pegfilgrastim
2) By Lenograstim: Injectable Formulations, Vial Formulations, Combination Therapies
3) By Filgrastim: Injectable Formulations, Pre-filled Syringes, Biosimilars Of Filgrastim
4) By Other Types: Filgrastim-sndz (Biosimilar), Novel G-CSF Products In Development, Combination Therapies With Other Growth Factors
Which Trends Are Contributing To Changes In The G-CSF (Granulocyte Colony Stimulating Factors) Market?
Major companies operating in the G-CSF (granulocyte colony stimulating factor) market are prioritizing technological advancements in hematopoietic therapies, specifically focusing on dimeric fusion protein design to enhance neutrophil production and reduce immunogenicity in long-acting G-CSF treatments. Dimeric fusion protein design entails linking two G-CSF molecules into a single protein, which extends its half-life and improves receptor activation without requiring PEGylation. For example, in November 2023, Evive Biotech Inc., a biopharmaceutical company based in Singapore, received U.S. Food and Drug Administration (FDA) approval for Ryzneuta (efbemalenograstim alfa). This long-acting biosimilar G-CSF is indicated for shortening the duration of neutropenia and febrile neutropenia in adults undergoing cytotoxic chemotherapy. Ryzneuta, a modified recombinant G-CSF, works by stimulating neutrophil production in the bone marrow, thereby accelerating the recovery of neutrophil counts. Key characteristics of Ryzneuta include long-acting dosing, compatibility with various chemotherapy regimens, and its availability in a ready-to-use prefilled syringe. It is used for the prevention of chemotherapy-induced neutropenia, stem cell mobilization, and supportive care for immunocompromised patients, providing benefits such as fewer injections, improved adherence, and better overall patient outcomes.
Which Companies Are Engaged In The G-CSF (Granulocyte Colony Stimulating Factors) Market Environment?
Major companies operating in the g-csf (granulocyte colony stimulating factors) market are Amgen Inc., Coherus Biosciences Inc., Sandoz, Biocon/Mylan, Teva Pharmaceuticals Inc., Chugai Pharma, Intalfarmaco Group, Pfizer, Sun Pharmaceutical Industries Limited, Cipla.
Access The Complete G-CSF (Granulocyte Colony Stimulating Factors) Market Report:
https://www.thebusinessresearchcompany.com/report/g-csf-global-market-report
Which Region Leads The G-CSF (Granulocyte Colony Stimulating Factors) Market By Size?
North America was the largest region in the G-CSF (granulocyte colony-stimulating factors) market in 2025. The regions covered in the g-csf (granulocyte colony stimulating factors) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Access G-CSF (Granulocyte Colony Stimulating Factors) Market Report for Deeper Competitive Insights
https://www.thebusinessresearchcompany.com/sample.aspx?id=3466&type=smp
Browse Through More Reports Similar to the Global G-CSF (Granulocyte Colony Stimulating Factors) Market 2026, By The Business Research Company
Therapeutic Proteins Market Report 2026
https://www.thebusinessresearchcompany.com/report/therapeutic-proteins-global-market-report
Thyroid Cancer Drugs Market Report 2026
https://www.thebusinessresearchcompany.com/report/thyroid-cancer-drugs-global-market-report
Biosimilar Market Report 2026
https://www.thebusinessresearchcompany.com/report/biosimilar-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model